JP2014504648A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014504648A5 JP2014504648A5 JP2013552663A JP2013552663A JP2014504648A5 JP 2014504648 A5 JP2014504648 A5 JP 2014504648A5 JP 2013552663 A JP2013552663 A JP 2013552663A JP 2013552663 A JP2013552663 A JP 2013552663A JP 2014504648 A5 JP2014504648 A5 JP 2014504648A5
- Authority
- JP
- Japan
- Prior art keywords
- heteroaryl
- aryl
- compound
- heterocyclyl
- independently
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims description 45
- 125000001072 heteroaryl group Chemical group 0.000 claims description 37
- 125000003118 aryl group Chemical group 0.000 claims description 36
- 125000000623 heterocyclic group Chemical group 0.000 claims description 28
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 17
- 239000000203 mixture Substances 0.000 claims description 15
- 229910052739 hydrogen Inorganic materials 0.000 claims description 14
- -1 —Z-aryl Chemical group 0.000 claims description 14
- 125000003710 aryl alkyl group Chemical group 0.000 claims description 13
- 125000000217 alkyl group Chemical group 0.000 claims description 12
- 125000002947 alkylene group Chemical group 0.000 claims description 12
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 11
- 239000001257 hydrogen Substances 0.000 claims description 10
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims description 10
- 239000008194 pharmaceutical composition Substances 0.000 claims description 10
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 10
- 125000002252 acyl group Chemical group 0.000 claims description 9
- 229910052799 carbon Inorganic materials 0.000 claims description 8
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims description 7
- 102100029111 Fatty-acid amide hydrolase 1 Human genes 0.000 claims description 7
- 108010046094 fatty-acid amide hydrolase Proteins 0.000 claims description 7
- 125000005843 halogen group Chemical group 0.000 claims description 7
- 125000004446 heteroarylalkyl group Chemical group 0.000 claims description 7
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 claims description 6
- 125000004432 carbon atom Chemical group C* 0.000 claims description 6
- 229910052760 oxygen Inorganic materials 0.000 claims description 6
- 150000003839 salts Chemical class 0.000 claims description 6
- 208000019116 sleep disease Diseases 0.000 claims description 6
- 229910052757 nitrogen Inorganic materials 0.000 claims description 5
- 125000003161 (C1-C6) alkylene group Chemical group 0.000 claims description 4
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims description 4
- 230000000202 analgesic effect Effects 0.000 claims description 4
- 125000004104 aryloxy group Chemical group 0.000 claims description 4
- 229910052794 bromium Inorganic materials 0.000 claims description 4
- 229910052801 chlorine Inorganic materials 0.000 claims description 4
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 4
- 239000003814 drug Substances 0.000 claims description 4
- CHNUOJQWGUIOLD-NFZZJPOKSA-N epalrestat Chemical compound C=1C=CC=CC=1\C=C(/C)\C=C1/SC(=S)N(CC(O)=O)C1=O CHNUOJQWGUIOLD-NFZZJPOKSA-N 0.000 claims description 4
- 229910052731 fluorine Inorganic materials 0.000 claims description 4
- 125000001188 haloalkyl group Chemical group 0.000 claims description 4
- 229910052736 halogen Inorganic materials 0.000 claims description 4
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 4
- 229910052740 iodine Inorganic materials 0.000 claims description 4
- 150000002825 nitriles Chemical class 0.000 claims description 4
- 125000004076 pyridyl group Chemical group 0.000 claims description 4
- 125000001424 substituent group Chemical group 0.000 claims description 4
- 229910052717 sulfur Inorganic materials 0.000 claims description 4
- 150000002367 halogens Chemical class 0.000 claims description 3
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 claims description 2
- 125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 claims description 2
- 208000027520 Somatoform disease Diseases 0.000 claims description 2
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims description 2
- 230000001754 anti-pyretic effect Effects 0.000 claims description 2
- 239000002221 antipyretic Substances 0.000 claims description 2
- 230000009286 beneficial effect Effects 0.000 claims description 2
- 125000000051 benzyloxy group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])O* 0.000 claims description 2
- 229930003827 cannabinoid Natural products 0.000 claims description 2
- 239000003557 cannabinoid Substances 0.000 claims description 2
- 125000005392 carboxamide group Chemical group NC(=O)* 0.000 claims description 2
- 150000001735 carboxylic acids Chemical class 0.000 claims description 2
- 229940111134 coxibs Drugs 0.000 claims description 2
- 239000003255 cyclooxygenase 2 inhibitor Substances 0.000 claims description 2
- 230000000147 hypnotic effect Effects 0.000 claims description 2
- 230000002401 inhibitory effect Effects 0.000 claims description 2
- 230000000631 nonopiate Effects 0.000 claims description 2
- 229940127240 opiate Drugs 0.000 claims description 2
- 208000027753 pain disease Diseases 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 claims description 2
- 125000003003 spiro group Chemical group 0.000 claims description 2
- 230000002459 sustained effect Effects 0.000 claims description 2
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims 1
- 239000002260 anti-inflammatory agent Substances 0.000 claims 1
- 229940121363 anti-inflammatory agent Drugs 0.000 claims 1
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims 1
- 238000000034 method Methods 0.000 description 8
- 208000020685 sleep-wake disease Diseases 0.000 description 2
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- LGEQQWMQCRIYKG-DOFZRALJSA-N anandamide Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(=O)NCCO LGEQQWMQCRIYKG-DOFZRALJSA-N 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- LGEQQWMQCRIYKG-UHFFFAOYSA-N arachidonic acid ethanolamide Natural products CCCCCC=CCC=CCC=CCC=CCCCC(=O)NCCO LGEQQWMQCRIYKG-UHFFFAOYSA-N 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 125000005842 heteroatom Chemical group 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161439415P | 2011-02-04 | 2011-02-04 | |
| US61/439,415 | 2011-02-04 | ||
| PCT/US2012/023718 WO2012106569A1 (en) | 2011-02-04 | 2012-02-03 | Alpha-ketoheterocycles and methods of making and using |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2014504648A JP2014504648A (ja) | 2014-02-24 |
| JP2014504648A5 true JP2014504648A5 (enExample) | 2015-03-12 |
| JP5871957B2 JP5871957B2 (ja) | 2016-03-01 |
Family
ID=46603088
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013552663A Expired - Fee Related JP5871957B2 (ja) | 2011-02-04 | 2012-02-03 | アルファ−ケト複素環ならびに作製法および使用法 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US9504675B2 (enExample) |
| EP (1) | EP2670245B1 (enExample) |
| JP (1) | JP5871957B2 (enExample) |
| AU (1) | AU2012212088B2 (enExample) |
| CA (1) | CA2825700A1 (enExample) |
| WO (1) | WO2012106569A1 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2825700A1 (en) | 2011-02-04 | 2012-08-09 | The Scripps Research Institute | Alpha-ketoheterocycles and methods of making and using |
| TWI631097B (zh) | 2012-07-27 | 2018-08-01 | 百健Ｍａ公司 | 作爲ｓ１ｐ調節劑及／或ａｔｘ調節劑之化合物 |
| PE20161035A1 (es) | 2013-03-15 | 2016-11-13 | Global Blood Therapeutics Inc | Compuestos y usos de estos para la modulacion de la hemoglobina |
| EA201992707A1 (ru) | 2013-11-18 | 2020-06-30 | Глобал Блад Терапьютикс, Инк. | Соединения и их применения для модуляции гемоглобина |
| CN104974106B (zh) * | 2014-04-04 | 2019-02-22 | 浙江普洛康裕制药有限公司 | 5-烷基-[1,3,4]-噁二唑-2-甲酸烷基酯的合成方法 |
| GB201802326D0 (en) | 2018-02-13 | 2018-03-28 | Ucl Business Plc | Gene therapy |
| CN113004193B (zh) * | 2021-02-07 | 2024-10-18 | 兰州康鹏威耳化工有限公司 | 硅化合物在环合反应中的用途 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004044169A2 (en) | 2002-11-14 | 2004-05-27 | The Scripps Research Institute | Crystalline form of fatty acid amine hydrolase (faah) |
| JP2009538358A (ja) * | 2006-05-26 | 2009-11-05 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | 脂肪酸アミド加水分解酵素のオキサゾリルピペリジン・モジュレーター |
| WO2008019357A2 (en) * | 2006-08-07 | 2008-02-14 | Ironwood Pharmaceuticals, Inc. | Indole compounds |
| WO2010005572A2 (en) | 2008-07-09 | 2010-01-14 | The Scripps Research Institute | Alpha-keto heterocycles as faah inhibitors |
| WO2010039186A2 (en) * | 2008-09-23 | 2010-04-08 | Renovis, Inc. | Compounds useful as faah modulators and uses thereof |
| CA2825700A1 (en) | 2011-02-04 | 2012-08-09 | The Scripps Research Institute | Alpha-ketoheterocycles and methods of making and using |
-
2012
- 2012-02-03 CA CA2825700A patent/CA2825700A1/en not_active Abandoned
- 2012-02-03 EP EP12741464.7A patent/EP2670245B1/en not_active Not-in-force
- 2012-02-03 WO PCT/US2012/023718 patent/WO2012106569A1/en not_active Ceased
- 2012-02-03 JP JP2013552663A patent/JP5871957B2/ja not_active Expired - Fee Related
- 2012-02-03 AU AU2012212088A patent/AU2012212088B2/en not_active Ceased
- 2012-02-03 US US13/983,369 patent/US9504675B2/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2014504648A5 (enExample) | ||
| JP2018524298A5 (enExample) | ||
| JP2020505396A5 (enExample) | ||
| JP2018520195A5 (enExample) | ||
| RU2011121567A (ru) | Изоиндолиновые соединения для применения при лечении рака | |
| JP2014037426A5 (enExample) | ||
| JP2010503688A5 (enExample) | ||
| RU2003132687A (ru) | Лечение диабета типа 2 ингибиторами дипептидилпептидазы iv | |
| RU99101081A (ru) | Режим введения ингибиторов н+, к+-атфазы | |
| JP2015511638A5 (enExample) | ||
| RU2015133450A (ru) | Соединения имидазопиридина и их применение | |
| JP2008509187A5 (enExample) | ||
| JP2015501833A5 (enExample) | ||
| RU2018106453A (ru) | Соединения | |
| RU2002123350A (ru) | Дипептиднитрильные ингибиторы катепсина К | |
| JP2013525458A5 (enExample) | ||
| RU2019141734A (ru) | Терапевтические соединения и композиции и способы их применения | |
| EA200601350A1 (ru) | Азотсодержащие гетероциклические производные и их фармацевтические применения | |
| JP2014502972A5 (enExample) | ||
| RU2012112050A (ru) | Производные дигидроптеридинона, способ их получения и фармацевтическое применение | |
| JP2013509392A5 (enExample) | ||
| RU2014152790A (ru) | Пирролопиразоновые ингибиторы танкиразы | |
| JP2017502092A5 (enExample) | ||
| JP2010522710A5 (enExample) | ||
| RU2013136895A (ru) | Новое бициклическое соединение или его соль |